Business Description
Cambium Bio Ltd
ISIN : AU0000327769
Compare
Compare
Traded in other countries / regions
CMB.Australia IPO Date
2013-09-19Description
Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.08 | |||||
| Equity-to-Asset | -12.32 | |||||
| Debt-to-Equity | -0.32 | |||||
| Debt-to-EBITDA | 7.38 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -10.1 | |||||
| 3-Year EPS without NRI Growth Rate | -14.5 | |||||
| 3-Year FCF Growth Rate | 34.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.41 | |||||
| 9-Day RSI | 45.77 | |||||
| 14-Day RSI | 49.3 | |||||
| 6-1 Month Momentum % | 25 | |||||
| 12-1 Month Momentum % | -58.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.08 | |||||
| Quick Ratio | 0.08 | |||||
| Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.3 | |||||
| Shareholder Yield % | 21.03 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -355.16 | |||||
| ROA % | -28.07 | |||||
| ROIC % | -97.37 | |||||
| ROC (Joel Greenblatt) % | 470 | |||||
| ROCE % | -280.59 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 105.26 | |||||
| EV-to-EBITDA | 105.26 | |||||
| EV-to-FCF | -11.8 | |||||
| Earnings Yield (Greenblatt) % | 0.96 | |||||
| FCF Yield % | -9.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cambium Bio Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.002 | ||
| Beta | -1.2 | ||
| Volatility % | 202.79 | ||
| 14-Day RSI | 49.3 | ||
| 14-Day ATR (A$) | 0.000913 | ||
| 20-Day SMA (A$) | 0.00945 | ||
| 12-1 Month Momentum % | -58.33 | ||
| 52-Week Range (A$) | 0.003 - 0.02 | ||
| Shares Outstanding (Mil) | 612.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cambium Bio Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cambium Bio Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cambium Bio Ltd Frequently Asked Questions
What is Cambium Bio Ltd(ASX:CMB)'s stock price today?
The current price of ASX:CMB is A$0.01. The 52 week high of ASX:CMB is A$0.02 and 52 week low is A$0.00.
When is next earnings date of Cambium Bio Ltd(ASX:CMB)?
The next earnings date of Cambium Bio Ltd(ASX:CMB) is .
Does Cambium Bio Ltd(ASX:CMB) pay dividends? If so, how much?
Cambium Bio Ltd(ASX:CMB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers